MedElevator Войти в исследования
← Поиск публикаций

DOI 10.34172/aim.33237

Медицинская библиотека · Archives of Iranian medicine · 2025

Efficacy and Safety of Tofacitinib in Lichen Planopilaris: A Retrospective Series of 74 Patients.

Goodarzi Mehdi, Dadkhahfar Sahar, Yahyaei Faranak, Razzaghi Zahra, Moravvej Hamideh

СтатьяНаблюдательное исследованиеПеревод в очереди

Аннотация

BACKGROUND

Lichen planopilaris (LPP) is a rare, inflammatory condition leading to scarring alopecia, predominantly affecting middle-aged women. Traditional treatments have shown limited efficacy, highlighting the need for novel therapeutic approaches. Tofacitinib, a Janus kinase (JAK) inhibitor, has shown promise in treating various autoimmune diseases, including autoimmune dermatological disorders. This study aims to evaluate the efficacy of tofacitinib in treating patients with LPP.

METHODS

We conducted a retrospective, single-center observational study at Shohadaye Tajrish Hospital, reviewing records of 74 patients with biopsy-confirmed LPP who had extensive and treatment-resistant disease. Patients were treated with tofacitinib 5 mg twice daily for at least 16 weeks. Efficacy was assessed using the LPP Activity Index (LPPAI), and adverse events were monitored.

RESULTS

This study evaluated 74 patients with LPP, predominantly female (83.3%), with a mean age of 46.64±8.05 years. The mean LPPAI score significantly decreased from 4.61±1.26 before treatment to 1.73±1.68 after six months (P<0.0001). Response rates varied: 21.62% within 1‒3 months, 24.32% within 3‒6 months, 33.78% within 6‒12 months, and 8.10% within 12‒24 months, with 6.75% showing no response. Adverse effects included headache (8.10%), hyperlipidemia (2.70%), elevated liver enzymes (5.40%), nausea (6.75%), and high blood pressure (4.15%).

CONCLUSION

Tofacitinib represents a promising treatment for LPP, providing significant improvement in disease activity for most patients. Further research is needed to refine treatment protocols, understand predictors of response, and address gender-specific adverse effects.

Для цитирования: Goodarzi Mehdi, Dadkhahfar Sahar, Yahyaei Faranak, Razzaghi Zahra, Moravvej Hamideh. Efficacy and Safety of Tofacitinib in Lichen Planopilaris: A Retrospective Series of 74 Patients.. Archives of Iranian medicine. 2025. DOI: 10.34172/aim.33237.

Предметные рубрики MeSH

Подготовка и перевод публикации
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Тип публикации указан по данным источника. Уровень доказательности автоматически не присваивается.